Boston Financial Management’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | $4.02M | Sell |
43,526
-895
| -2% | -$80.6K | 0.12% | 109 |
|
|
2024
Q3 | $3.72M | Sell |
44,421
-2,234
| -5% | -$170K | 0.11% | 115 |
|
|
2024
Q2 | $3.2M | Sell |
46,655
-1,142
| -2% | -$76.2K | 0.1% | 118 |
|
|
2024
Q1 | $3.5M | Buy |
47,797
+4,002
| +9% | +$308K | 0.11% | 113 |
|
|
2023
Q4 | $3.55M | Sell |
43,795
-156
| -0.4% | -$12.1K | 0.12% | 109 |
|
|
2023
Q3 | $3.29M | Sell |
43,951
-3,600
| -8% | -$277K | 0.12% | 109 |
|
|
2023
Q2 | $3.66M | Sell |
47,551
-1,389
| -3% | -$111K | 0.13% | 107 |
|
|
2023
Q1 | $4.06M | Buy |
48,940
+1,694
| +4% | +$140K | 0.16% | 105 |
|
|
2022
Q4 | $4.06M | Buy |
47,246
+1,356
| +3% | +$107K | 0.16% | 99 |
|
|
2022
Q3 | $2.83M | Buy |
45,890
+976
| +2% | +$61.5K | 0.12% | 108 |
|
|
2022
Q2 | $2.78M | Buy |
44,914
+1,268
| +3% | +$78.5K | 0.12% | 104 |
|
|
2022
Q1 | $2.6M | Sell |
43,646
-5,658
| -11% | -$362K | 0.1% | 112 |
|
|
2021
Q4 | $3.58M | Sell |
49,304
-10,198
| -17% | -$702K | 0.13% | 88 |
|
|
2021
Q3 | $4.16M | Sell |
59,502
-177,079
| -75% | -$12.4M | 0.17% | 80 |
|
|
2021
Q2 | $16.3M | Buy |
236,581
+8,712
| +4% | +$582K | 0.66% | 46 |
|
|
2021
Q1 | $14.7M | Buy |
227,869
+19,158
| +9% | +$1.24M | 0.65% | 47 |
|
|
2020
Q4 | $12.2M | Sell |
208,711
-63,939
| -23% | -$3.86M | 0.55% | 50 |
|
|
2020
Q3 | $17.2M | Buy |
272,650
+5,375
| +2% | +$373K | 0.84% | 37 |
|
|
2020
Q2 | $20.6M | Buy |
267,275
+12,678
| +5% | +$972K | 1.11% | 30 |
|
|
2020
Q1 | $19M | Buy |
254,597
+50,248
| +25% | +$3.47M | 1.22% | 29 |
|
|
2019
Q4 | $13.3M | Sell |
204,349
-36,884
| -15% | -$2.4M | 0.73% | 45 |
|
|
2019
Q3 | $15.3M | Sell |
241,233
-2,918
| -1% | -$191K | 0.87% | 38 |
|
|
2019
Q2 | $16.5M | Sell |
244,151
-2,817
| -1% | -$185K | 0.95% | 35 |
|
|
2019
Q1 | $16.1M | Buy |
246,968
+24,776
| +11% | +$1.65M | 0.98% | 34 |
|
|
2018
Q4 | $13.9M | Sell |
222,192
-24,704
| -10% | -$1.73M | 0.96% | 37 |
|
|
2018
Q3 | $19.1M | Buy |
246,896
+48,773
| +25% | +$3.68M | 1.13% | 26 |
|
|
2018
Q2 | $14M | Sell |
198,123
-4,783
| -2% | -$338K | 0.95% | 38 |
|
|
2018
Q1 | $15.3M | Sell |
202,906
-3,572
| -2% | -$284K | 1.05% | 28 |
|
|
2017
Q4 | $14.8M | Buy |
206,478
+2,900
| +1% | +$220K | 0.99% | 31 |
|
|
2017
Q3 | $16.5M | Sell |
203,578
-297
| -0.1% | -$22.7K | 1.17% | 17 |
|
|
2017
Q2 | $14.4M | Buy |
203,875
+130,315
| +177% | +$8.67M | 1.04% | 23 |
|
|
2017
Q1 | $5M | Sell |
73,560
-348
| -0.5% | -$24.5K | 0.37% | 92 |
|
|
2016
Q4 | $5.29M | Sell |
73,908
-13,821
| -16% | -$1.03M | 0.42% | 90 |
|
|
2016
Q3 | $6.94M | Buy |
87,729
+179
| +0.2% | +$14.5K | 0.57% | 65 |
|
|
2016
Q2 | $7.3M | Buy |
87,550
+9,446
| +12% | +$838K | 0.6% | 58 |
|
|
2016
Q1 | $7.17M | Buy |
78,104
+530
| +0.7% | +$47.8K | 1.08% | 26 |
|
|
2015
Q4 | $7.85M | Sell |
77,574
-11,037
| -12% | -$1.15M | 1.13% | 21 |
|
|
2015
Q3 | $8.7M | Sell |
88,611
-1,424
| -2% | -$158K | 1.23% | 15 |
|
|
2015
Q2 | $10.5M | Buy |
90,035
+3,913
| +5% | +$428K | 1.36% | 14 |
|
|
2015
Q1 | $8.45M | Buy |
86,122
+3,266
| +4% | +$332K | 1.06% | 25 |
|
|
2014
Q4 | $7.81M | Buy |
82,856
+1,110
| +1% | +$115K | 0.98% | 28 |
|
|
2014
Q3 | $8.7M | Sell |
81,746
-6,751
| -8% | -$661K | 1.14% | 21 |
|
|
2014
Q2 | $7.34M | Sell |
88,497
-114
| -0.1% | -$8.87K | 0.97% | 30 |
|
|
2014
Q1 | $6.28M | Sell |
88,611
-3,763
| -4% | -$295K | 0.84% | 36 |
|
|
2013
Q4 | $6.94M | Buy |
92,374
+119
| +0.1% | +$8.29K | 0.95% | 31 |
|
|
2013
Q3 | $5.8M | Sell |
92,255
-9,835
| -10% | -$588K | 0.87% | 36 |
|
|
2013
Q2 | $5.23M | Buy |
+102,090
| New | +$5.32M | 0.81% | 39 |
|
Other funds holding GILD
Boston Financial Management's GILD Position: Q4 2024 in Review
Boston Financial Management reduced its Gilead Sciences (GILD) stake by 2% in Q4 2024, selling an estimated $80.6K and leaving 43,526 shares worth $4.02M. The position accounts for 0.12% of the portfolio, ranked #109.
Boston Financial Management first reported a position in GILD in Q2 2013 and has held it in 47 quarters since. The position peaked at $20.6M in Q2 2020. 1,888 funds tracked by Wall St. Rank hold GILD as of Q4 2024.
- Boston Financial Management held 43,526 shares of Gilead Sciences worth $4.02M as of Q4 2024.
- Boston Financial Management sold 895 Gilead Sciences shares in Q4 2024, an estimated $80.6K.
- Gilead Sciences made up 0.12% of Boston Financial Management's portfolio in Q4 2024, its #109 holding.
- Boston Financial Management first reported a position in Gilead Sciences in Q2 2013 and has held it in 47 quarters since.
- Boston Financial Management's Gilead Sciences position peaked at $20.6M in Q2 2020.
- 1,888 funds tracked by Wall St. Rank held Gilead Sciences as of Q4 2024.
Based on Boston Financial Management's 13F filing for Q4 2024, filed 3 Feb 2025.